Evidence map›Paper›PMID 40878905›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Associations between fluid biomarkers and PET imaging ([11C]UCB-J) of synaptic pathology in Alzheimer's disease.

Johanna Nilsson, Adam P Mecca, Nicholas J Ashton, Elaheh Salardini, Ryan S O'Dell, Richard E Carson, Andrea L Benedet, Kaj Blennow, Henrik Zetterberg, Christopher H van Dyck and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Associations between fluid biomarkers and PET imaging ([11C]UCB-J) of synaptic pathology in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Johanna NilssonInstitute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-2856-6060
Adam P MeccaYale Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, USA.
Nicholas J AshtonInstitute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Elaheh SalardiniYale Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, USA.
Ryan S O'DellYale Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, USA.
Richard E CarsonDepartment of Radiology and Biomedical Imaging, Yale University School of Medicine, New Haven, USA.
Andrea L BenedetInstitute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Kaj BlennowInstitute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Henrik ZetterbergInstitute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Christopher H van DyckYale Alzheimer's Disease Research Unit, Yale School of Medicine, New Haven, USA.
Ann BrinkmalmInstitute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.

Funding

Yale Alzheimer Disease Research CenterP30AG066508 · NIA · YALE UNIVERSITY · PI STEPHEN M STRITTMATTER, CHRISTOPHER H VAN DYCK · 2020 to 2026
$30.2M
Yale Alzheimer Disease Research CenterP50AG047270 · NIA · YALE UNIVERSITY · PI MAROTTOLI, RICHARD · 2015 to 2019
$8.3M
PET Imaging of SV2A and Other Biomarkers in Alzheimer's DiseaseR01AG062276 · NIA · YALE UNIVERSITY · PI VAN DYCK, CHRISTOPHER H · 2018 to 2022
$5.5M
PET Imaging of Synaptic Density in Alzheimers DiseaseR01AG052560 · NIA · YALE UNIVERSITY · PI CARSON, RICHARD E., VAN DYCK, CHRISTOPHER H · 2017 to 2020
$3.2M
The effects of iron on oxidative stress and Alzheimer's biomarkers in amyloid-positive and negative elderly normalR01AG068398 · NIA · WEILL MEDICAL COLL OF CORNELL UNIV · PI CHIANG, GLORIA CHIA-YI · 2020 to 2024
$2.8M
Alzheimer Drug Discovery Foundation 201809-2016862Alzheimer Drug Discovery Foundation (ADDF), USA RDAPB-201809-2016615Alzheimer's Association 2021 Zenith Award ZEN-21-848495European Research Council 681712European Union Joint Program for Neurodegenerative Disorders JPND2019-466-236European Union's HorizonHjärnfonden FO2019-0228Hjärnfonden, Sweden FO2017-0243National Institutes of Health (NIH), USA 1R01AG068398-01NIA NIH HHS P30 AG066508NIA NIH HHS P30AG066508NIA NIH HHS P50 AG047270NIA NIH HHS P50AG047270NIA NIH HHS R01 AG052560NIA NIH HHS R01AG052560NIA NIH HHS R01 AG062276NIA NIH HHS R01AG062276NIA NIH HHS R01 AG068398Olav Thon FoundationResearch and Innovation Programme under the Marie Skłodowska-Curie grant agreement 860197Swedish Alzheimer Foundation AF-742881Swedish Research Council 2017-00915Swedish Research Council 2018-02532Swedish State Support for Clinical Research ALFGBG-720931Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement ALFGBG-715986the AD Strategic Fund and the Alzheimer's Association ADSF-21-831376-Cthe AD Strategic Fund and the Alzheimer's Association ADSF-21-831377-Cthe AD Strategic Fund and the Alzheimer's Association ADSF-21-831381-CThe Erling-Persson Family FoundationThe Foundation of Gamla tjänarinnorUK Dementia Research Institute at UCL
6 · The paper itself

Abstract

introductionPositron emission tomography (PET) imaging with ligands for synaptic vesicle glycoprotein 2A (SV2A) has emerged as a promising methodology for measuring synaptic density in Alzheimer's disease (AD). We investigated the relationship between SV2A PET and CSF synaptic protein changes of AD patients.

methodTwenty-one participants with early AD and seven cognitively normal (CN) individuals underwent [

resultsIn the AD group, higher levels of syntaxin-7 and PEBP-1 were associated with lower global synaptic density. In the total sample, lower global synaptic density was associated with higher levels of AP2B1, neurogranin, γ-synuclein, GDI-1, PEBP-1, syntaxin-1B, and syntaxin-7 but not with the levels of the neuronal pentraxins or 14-3-3 zeta/delta.

conclusionReductions of synaptic density found in AD compared to CN participants using [ HIGHLIGHTS: A panel of synaptic proteins was quantified in the CSF using mass spectrometry. SV2A ([

Indexed as

Alzheimer DiseasePositron-Emission TomographySynapsesAgedAged, 80 and overBiomarkersBrainFemaleHumansMaleMembrane GlycoproteinsMiddle AgedNerve Tissue ProteinsBiomarkersMembrane GlycoproteinsNerve Tissue ProteinsSV2A protein, humanAlzheimer's diseasebiomarkersmass spectrometrySV2Asynaptic pathology

Identifiers

PMID40878905
PMCPMC12245979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.